medigraphic.com
ISSN 0187-5337 (Print)
Instituto Nacional de Perinatología

2009, Number 3

<< Back Next >>

Perinatol Reprod Hum 2009; 23 (3)

Clinical aspects of erectile dysfunction in patients with type 2 diabetes mellitus

Juárez-Bengoa A, Pimentel-Nieto D, Morales-Carmona F

Language: Spanish
References: 56
Page: 169-177
PDF size: 109.96 Kb.


ABSTRACT

Vascular and neurological abnormalities that causes diabetes mellitus on the sexual organs lead to erectile dysfunction, a problem with a prevalence of 35% to 75% among diabetics of all ages, representing a rate three times higher than in non-diabetic men. The severity of the problem is correlated with glycemic control, duration of diabetes mellitus, and complications caused by diabetes mellitus. Moreover of the organic problem, psychological alterations are developed, which together lead to a deterioration in the quality of life. For treatment, the first consideration is elimination of factors that contribute to vascular disease, so it is necessary to control blood sugar. It is also important to avoid, as far as practicable, drugs having adverse effects on erectile function. The first-line drug treatment are 5-phosphodiesterase inhibitors including sildenafil, vardenafil, and tadalafil, which have shown similar efficacy on erectile dysfunction. Other therapeutic alternatives are apomorphine, and vacuum devices. A second line of treatment consists of intracavernous injections or urethral suppositories of prostaglandin E1. Prosthesis are a third line of management when other options have failed or are contraindicated. Psychological treatment should be considered simultaneously for the integral treatment of the patient.


REFERENCES

  1. Basu A, Ryder R. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004; 64(23): 2667-88.

  2. Ellenberg M. Impotence in diabetes: the neurologic factor. Ann Intern Med 1991; 75: 213-9.

  3. NIH Consensus development. Panel on Impotence. JAMA 1993; 270: 53-90.

  4. Feldman H, Goldstein I, Hatzichristou D et al. Impotence and its medical psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61. Morley J. Impotence. Am J Med 1986; 80: 897-905.

  5. Braun M, Wassmer G, Klotz T et al. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res 2000; 12: 305-11.

  6. Morley J. Impotence. Am J Med 1986; 80: 897-905.

  7. Mc Culloch D, Campell I, Wu F, Prescott R, Clarke B. The prevalence of diabetic impotence. Diabetologia 1980; 18: 279-83.

  8. Leyva-Gonzales F. Diabetes mellitus tipo 2 y disfunción sexual eréctil. Rev Med IMSS México 1996; 342: 139-43.

  9. Fedele D, Bortolotti A, Coscelli C. Erectile dysfunction among type I and type 2 diabetics in Italy. Int J Epidemiol 2000; 29: 524-31.

  10. Lipshultz L, Kim E. Treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 465-6.

  11. Fedele D, Coscelli C. Cucinotta D. Incidence of erectile dysfunction in Italian men with diabetes. J Urol 2001; 166: 1368-71.

  12. Johannes C, Araujo A, Feldman H, Derby C, Kleinman K, McKinlay J. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-3.

  13. Fedele D, Coscelli C, Santeusanjo F et al. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 1998; 21: 1973-7.

  14. Brown J, Wessells H, Chancellor M. Urologic complications of diabetes. Diabetes Care 2000; 28(1): 177-85.

  15. Arrondo J. Recuerdo anatomofisiológico de la erección. En: Práctica Andrológica. Pomerol J, Arrondo J. editores. Ediciones Científicas y Técnicas, S.A. Barcelona 1994.

  16. Lue T. Fisiología de la erección peneana y fisiopatología de la disfunción eréctil y el priapismo 1740. En Campbell Urología Tomo 2 Ed. Médica Panamericana. 2002.

  17. Koolman J, Röhm K. Hormonas. En: Bioquímica Texto y Atlas. Ed. Médica Panamericana 3ª. Ed. 2004.

  18. Dean R, Lue T. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005; 32(4): 379.

  19. Basu A, Ryder R. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004; 64(23): 2667-88.

  20. Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S. Selective nitrergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. Br J Pharmacol 1999; 128: 1804-12.

  21. Tuncayengin A, Biri H, Onaran M, Sen I, Tuncayengin O, Polat F et al. Cavernosal tissue nitrite, nitrate, malondialdehyde and glutathione levels in diabetic and non-diabetic erectile dysfunction. Int J Androl 2003; 26: 250-4.

  22. Cartledge J, Eardley I, Morrison J. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87-402-7.

  23. Sing R, Barden A, Mori T. Advanced glycation end-products: a review. Diabetología 2001; 44: 129-46.

  24. Bucala R, Tracey K, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 1991; 87: 432-8.

  25. Foresta C, Caretta N, Palego P, Selice R, Garolla A, Ferlin A. Diagnosing erectile dysfunction: flor-chart. Int J Androl. 2005; 28 Suppl 2: 64-8.

  26. Foresta C, Caretta N, Aversa A, Bettocchi C, Corona G, Mariani S, Rossato M. Erectile dysfunction: symptom or disease? J Endocrinol Invest. 2004; 27(1): 80-95.

  27. Barroso AJ, Ugarte RF, Pimentel-Nieto D. Prevalencia de disfunción eréctil en hombres de 18 a 40 años en México y factores de riesgo asociados. Perinatol Reprod Hum 2001; 15: 254-61.

  28. Rubio E, Díaz, J. Las disfunciones sexuales. En: Consejo Nacional de Población (Editor) Antología de la Sexualidad Humana. México. Ed. Porrúa. 1994; (3): 203-46.

  29. Sánchez BC, Carreño MJ, Guerra RG, Martínez RS, Aldana CE. Disfunción sexual masculina y su relación con el rol de género y asertividad. Perinatol Reprod Hum 2002; 16: 123-31.

  30. Manual Diagnóstico y Estadístico de las Enfermedades Mentales. DSM - IV. Ed. Masson, SA. 1996. México, DF.

  31. Wyllie MG. The underlying pathophysiology and causes of erectile dysfunction. Clin Cornerstone. 2005; 7(1): 19-27.

  32. Roose SP, Seidman SN. Sexual activity and cardiac risk: is depression a contributing factor? Am J Cardiol. 2000; 86(2A): 38F-40F.

  33. Meleuman EJ. Prevalence of erectile dysfunction: need for treatment? Int J Impot Res. 2002; 14 Suppl 1: S22-8.

  34. De Berardis G, Pellegrini F, Franciosi M, Belfiglio M, di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A; QuED (Quality of Care and Outcomes in Type 2 diabetes) Study Group. Longitudinal assessment of quality of life in patients with type 2 diabetes and self-reported erectile dysfunction. Diabetes Care. 2005; 28(11): 2637-43.

  35. Sánchez BC, Morales-Carmona F, Pimentel-Nieto D, Carreño MJ, Guerra RG. Disfunción sexual masculina y calidad de la comunicación marital. Un estudio comparativo. Perinatol Reprod Hum 2002; 16: 16-25.

  36. Foresta C, Argiolas A, Basi P, Bettocchi C, Fabbri A, Gentile V, Ghirlanda G, Isidori A, Jannini E, Ledda A, Maggi M, Rosano GM, Spera G, Caretta N. Clinical and diagnostic approach to erectile dysfunction. Ann Ital Med Int 2003; 18(4): 204-18.

  37. Lara CMA. Masculinidad, feminidad y salud mental. Importancia de las características no deseables de los roles de género. Salud Mental 1991; 1:12-8.

  38. Moore Ch, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8(6): 685-92.

  39. Vickers M, Wright E. Erectile dysfunction in the patient with diabetes mellitus. Am J Manag Care 2004; 10(1, Suppl): S3-11.

  40. Langry H, Markham A. Sildenafil: a review of its use in erectile dysfunction. Drugs 1999; 57(6): 967-89.

  41. Rendell M, Rajfer J, Wicker P. Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA 1999; 281(5): 421-6.

  42. Boulton A, Selam J, Sweeney M et al. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus. Diabetologia 2001; 44: 1296-301.

  43. Hellstrom W, Gittelman M, Karlin G. Vardenafil for the treatment of erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.

  44. Goldstein I, Young J, Fischer J. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. Diabetes Care 2003; 26: 777-83.

  45. Vickers M, Satyanarayana R. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2002; 14: 466-71.

  46. Saenz I, Anglin G, Knight J et al. Effects of taldalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159-64.

  47. Souverein P, Egberts A, Meuleman E, Urquhart J, Leufkens H. Incidence and determinants of sildenafil users. Int J Impot Res 2002; 14: 259-65.

  48. Dula E, Bukofser S, Perdok R et al. Double-blind crossover comparison of 3 mg apomorphine SL, with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-64.

  49. Heaton P, Lording d, Liu S et al. Intracavernosal alprostadil is less effective for the treatment of erectile dysfunction I diabetic men. Int J Impot Res 2001; 13: 317-21.

  50. Lue T. Erectile dysfunction. N Engl J Med 2000; 342(24): 1802-13.

  51. Moemen M, Hamed H, Kamel I, Shamioul R, Ghanem H. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances. Int J Impot Res 2004; 16: 143-5.

  52. Irwin M, Kata E. High attrition rate with intracavernous injection of prostaglandin E1 for impotency. Urology 1994; 43: 84-7.

  53. Beaser R, Vander H, Jacobson A, Flood T, Pesautels R. Experience with penile prostheses in the treatment of impotence in diabetic men. JAMA 19982; 248: 943-8.

  54. Moncada I, Martínez-Salamanca J, Allona A, Hernández C. Current role of penile implants for erectile dysfunction. Curr Opin Urol 2004; 14: 375-80.

  55. Giommi R, Corona G, Maggi M. The therapeutic dilemma: how to use psychotherapy. Int J Androl. 2005; 28 Suppl 2: 81-5.

  56. Riley A. The role of the partner in erectile dysfunction and treatment. Int J Impot Res 2002; 14 Suppl 1: S105-9.




2020     |     www.medigraphic.com